Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's ...

In addition to lowering its price target from $105 to $64 to market perform, BMO lowered its rating on Novo Nordisk’s shares ...

Both the FDA and Novo Nordisk are advising patients and providers to check their supplies of Ozempic for counterfeit product. Individuals in possession of a counterfeit product are urged to call Novo ...

Ozempic, originally prescribed for type 2 diabetes, is now widely used off-label for weight loss, but rapid results can lead ...

Eli Lilly plans to manufacture its new weight-loss pill in the US for patients around the world as Trump presses companies to ...

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose ...